FDA | GovernmentCIO Media & Research

FDA

Newly confirmed CIO Vid Desai discusses how his role has evolved following the creation of FDA's Digital Transformation Office.
Both Moderna and Johnson & Johnson COVID-19 vaccines are approved for some vaccinated individuals while the agency reviews more data.
A group of IT specialists and scientists are fostering collaboration to enact transformational changes across the agency.
Dr. Rochelle Walensky discusses CDC’s booster dose decision for some individuals and next steps in the regulatory process.
With novel health solutions, drug manufacturers undergo a strict process to get their products to market.
FDA’s biologics leader explains progress with COVID-19 vaccines and response to emerging variants.
The agency is taking on tech modernization with new office and new appointments.
The new legislation also builds on White House infrastructure goals to improve health care, drug development and more.
A new initiative aims to build a “community of interoperability” to improve diagnostics and standards.
The agency's tech posture is helping it review unexpected amounts of applications for new tobacco products.
Data management and digital tools are driving FDA’s efforts to respond to the next wave of COVID-19 demands.
A Presidential Innovation Fellow is helping the agency improve workflows and ultimately ensure safety of the drugs and treatments it regulates.
A permanent supply chain program will help the agency prevent shortages of medical devices.
Leveraging patient experience data for product development requires strong workforce readiness.
Agency leaders helped lead FDA’s COVID-19 emergency response and improved processes to expedite delivery of critical medical supplies.
Leaders across the Center for Drug Evaluation and Research are applying lessons learned from the pandemic on its response to therapies for emerging variants.
As federal agencies modernize systems and processes, managing the workforce remains a crucial component to managing change.
The agency outlines exemptions and waivers that maintain strengthened supply chain efforts while also enabling a strong pandemic response.
Federal agencies have refined their cybersecurity practices to adapt to both newfound threats and the broad shift to remote work.
CDO Ram Iyer noted FDA’s data progress preparing for emerging technologies since the launch of its roadmap in March 2021.